O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.
President-elect Donald Trump interviewed what appear to be two unconventional candidates for FDA commissioner, but at least one other potential selection remains among those that could receive the nomination.
The transition team indicated that Trump met with Jim O'Neill, managing director of Mithril Capital Management, and Balaji Srinivasan, partner...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
